Methodology

How HR01.1 was formulated.

READING TIME · 12 MIN · REVISED APR 2026 · R.01

HR01.1 is a daily oral protocol formulated around ten actives selected from the published nutritional literature on hair. This document explains how we arrived at each active, why each is dosed at the level it is, and the framework that holds the formulation together.


The four contributors framework

Hair growth, shedding, and renewal are governed by biological processes that nutritional formulations can address in part. HR01.1 is structured around four contributors to follicle and hair-fibre health that the published literature has investigated most extensively.

The framework is descriptive, not prescriptive. Hair biology is interconnected, these contributors do not operate in isolation, and no single contributor governs the hair you have. The framework exists because it makes the formulation legible: each active in HR01.1 can be located within one or more of the four contributors.

FIG. 01 · THE FOUR CONTRIBUTORS
01 · HORMONAL
Androgen-related follicle behaviour.
Saw Palmetto Extract
Pumpkin Seed Oil
02 · OXIDATIVE
Cellular antioxidant defences.
Tocotrienol Complex
Selenium
03 · STRUCTURAL
Keratin synthesis and disulphide bond formation.
L-Cystine
L-Lysine
MSM
Zinc
04 · STRESS-RELATED
Stress-response and hair growth cycle.
Ashwagandha Extract
Vitamin D3

01. Hormonal

The endocrine system shapes follicle behaviour over time. Androgens, particularly dihydrotestosterone (DHT), are the most extensively studied hormonal influence on the hair growth cycle, and follicle sensitivity to them varies by genetics, age, and life stage.

The published nutritional literature has investigated several botanicals in the context of androgen-related hair concerns. HR01.1 includes two of these.

ACTIVES IN HR01.1 ADDRESSING THIS CONTRIBUTOR

Saw Palmetto Extract — 320 mg
Pumpkin Seed Oil — 400 mg

02. Oxidative

Hair follicles are metabolically active and produce reactive oxygen species as a by-product of normal cellular function. Cellular antioxidant defences counter this, and their efficiency depends on nutritional status.

The published research has investigated antioxidant compounds, particularly members of the vitamin E family and trace minerals with antioxidant cofactor function in this context.

ACTIVES IN HR01.1 ADDRESSING THIS CONTRIBUTOR

Tocotrienol Complex — 100 mg
Selenium — 55 µg

03. Structural

Hair fibre is composed primarily of keratin, a sulphur-rich fibrous protein assembled from specific amino acids. The synthesis of keratin requires both the amino acid building blocks and mineral cofactors involved in disulphide bond formation.

This is the contributor with the clearest authorised regulatory framework: zinc and selenium both have GB-authorised health claims for the maintenance of normal hair.

ACTIVES IN HR01.1 ADDRESSING THIS CONTRIBUTOR

L-Cystine — 450 mg
L-Lysine — 450 mg
MSM — 500 mg
Zinc — 15 mg

04. Stress-related

Physiological and psychological stress alter the hair growth cycle. Cortisol patterns, sleep quality, and overall physiological load influence the proportion of follicles in active growth (anagen) versus shedding (telogen) phase.

The published research has investigated nutritional support for stress-response systems, including adaptogenic botanicals long used in traditional medicine and now examined in modern clinical trials.

ACTIVES IN HR01.1 ADDRESSING THIS CONTRIBUTOR

Ashwagandha Extract — 300 mg
Vitamin D3 — 50 µg


Per-active dose rationale

Each active in HR01.1 is dosed at a level reflecting the published nutritional literature, balanced against safe upper intake limits where these are set by UK guidance, and balanced against the formulation's combined load within a four-capsule daily dose. Where the dose in HR01.1 sits below the levels investigated in monotherapy clinical trials, this is stated and explained.

FIG. 02 · DOSE RATIONALE SUMMARY
Active HR01.1 Dose Literature Range Reference
Pumpkin Seed Oil 400 mg 400 mg Cho et al. 2014
Saw Palmetto Extract 320 mg 100–320 mg Evron et al. 2020
Tocotrienol Complex 100 mg 100 mg Beoy et al. 2010
L-Cystine 450 mg 250–500 mg* VKM 2016
L-Lysine 450 mg 1,000–1,500 mg† Almohanna et al. 2019
MSM 500 mg 1,000–3,000 mg† See rationale below
Ashwagandha Extract 300 mg 300–600 mg Chandrasekhar et al. 2012
Vitamin D3 50 µg ≤100 µg UK SACN guidance
Zinc 15 mg ≤25 mg UK SACN guidance
Selenium 55 µg ≤300 µg UK SACN guidance

* Standard standalone supplement range for L-Cystine; safe upper intake assessment 750 mg/day for adults (VKM 2016).
† HR01.1 dose is below the standalone trial range. See per-active rationale for the formulation prioritisation.

Pumpkin Seed Oil — 400 mg

Cold-pressed oil from Cucurbita pepo seeds, naturally rich in phytosterols (including delta-7 phytosterols), unsaturated fatty acids, and tocopherols.

The 400 mg daily dose reflects the protocol used in Cho et al. (2014), a 24-week randomised, double-blind, placebo-controlled trial published in Evidence-Based Complementary and Alternative Medicine. The trial investigated cold-pressed pumpkin seed oil at 400 mg daily in 76 men with mild-to-moderate androgenetic alopecia.

Saw Palmetto Extract — 320 mg

Lipophilic fruit extract from Serenoa repens, naturally containing fatty acids, phytosterols, and small concentrations of polyphenolic compounds. The fatty acid fraction is the most studied compositional feature.

The 320 mg daily dose sits at the upper end of the dose range investigated in published trials of saw palmetto in androgen-related contexts. Evron et al. (2020), a systematic review published in Skin Appendage Disorders, identified an investigated dose range of 100–320 mg across the published literature on oral and topical saw palmetto supplements in alopecia.

Tocotrienol Complex — 100 mg

A mixed-isoform extract of tocotrienols, the less-common members of the vitamin E family, distinct from the alpha-tocopherol found in most vitamin E supplements. Sourced from palm fruit.

The 100 mg daily dose reflects the protocol used in Beoy et al. (2010), an 8-month trial published in Tropical Life Sciences Research. The trial investigated mixed tocotrienol supplementation at 100 mg daily in 38 adult volunteers with hair loss.

L-Cystine — 450 mg

A sulphur-bearing amino acid composed of two cysteine residues linked by a disulphide bond. L-Cystine is one of the principal amino acids in keratin (which contains approximately 16% L-cystine by composition) and is structurally significant in hair fibre formation.

The 450 mg daily dose sits within the standard standalone supplemental range for L-Cystine (typically 250–500 mg per capsule across European nutritional supplements) and well within the upper safe intake assessment of 750 mg/day for adults established by the Norwegian Scientific Committee for Food Safety. This is meaningfully higher than the L-Cystine content investigated in published multi-ingredient hair supplement trials, including Lengg et al. (2007), where L-Cystine was one component within a B-vitamin and medicinal yeast complex at lower per-dose levels.

L-Lysine — 450 mg

An essential amino acid (one the human body cannot synthesise from other compounds) involved in collagen synthesis and iron absorption. While L-Lysine is not itself a primary structural component of hair, dietary lysine status interacts with iron metabolism, which is required for hair follicle cycling.

The role of L-Lysine in hair-related nutrition has been reviewed in Almohanna et al. (2019) in Dermatology and Therapy and Guo and Katta (2017) in Dermatology Practical & Conceptual. Published clinical investigations of L-Lysine specifically for hair have used 1,000–1,500 mg daily, paired with iron supplementation in women with chronic telogen effluvium and low ferritin status.

The 450 mg daily dose in HR01.1 is below those trial levels. This is a deliberate formulation decision. A four-capsule daily dose carries a finite mass of actives; we have prioritised that capsule load toward the actives with the most direct evidence in hair-specific clinical research — Pumpkin Seed Oil, Saw Palmetto, Tocotrienol, Ashwagandha, and the regulated minerals — and dosed those at the levels investigated in the literature. L-Lysine is included to support the formulation's amino acid profile alongside L-Cystine, not as a standalone replacement for the iron-paired protocols described in the literature. Customers with diagnosed iron-related telogen effluvium should consult a healthcare professional, who can advise on iron supplementation and L-Lysine dosing appropriate to their ferritin status.

MSM — 500 mg

Methylsulfonylmethane, an organic sulphur compound. MSM functions as a bioavailable sulphur donor, and sulphur is required for keratin synthesis (the disulphide bonds that give hair its structural integrity are sulphur-based).

Published clinical research on MSM specifically for hair has typically investigated doses of 1,000–3,000 mg daily as a standalone intervention. The 500 mg daily dose in HR01.1 is below those levels, by deliberate formulation decision. Capsule load is finite; sulphur is already supplied through L-Cystine, which sits at meaningful nutritional levels in the formulation. MSM at 500 mg is included as a complementary sulphur source rather than as a primary intervention, with the priority of the protocol allocated to actives with stronger and more direct hair-specific clinical evidence.

Ashwagandha Extract — 300 mg

Root extract of Withania somnifera, traditionally used in Ayurvedic practice and now widely studied in modern nutritional research. Contains naturally occurring withanolides as the characterising compounds.

The 300 mg daily dose sits at the lower end of doses investigated in clinical research on standardised ashwagandha root extract. Chandrasekhar et al. (2012), a 60-day randomised, double-blind, placebo-controlled trial published in the Indian Journal of Psychological Medicine, investigated 300 mg of high-concentration full-spectrum ashwagandha root extract twice daily in 64 adults under stress. We have selected the once-daily 300 mg dose to deliver ashwagandha at the lower end of the investigated range. Note: ashwagandha is currently under active review by the UK Food Standards Agency Committee on Toxicity. We monitor this review closely and will reformulate if regulatory guidance changes.

Vitamin D3 — 50 µg (1,000% NRV)

Cholecalciferol, the form of vitamin D synthesised by the human skin in response to UVB exposure. The active form involved in cellular signalling. Sourced from lichen (vegan-suitable).

The 50 µg (2,000 IU) daily dose reflects the upper end of doses investigated in the published research on vitamin D status, balanced against UK Tolerable Upper Intake Level guidance (100 µg/day from all sources). This dose is appropriate for individuals not taking other vitamin D supplements; cumulative intake guidance applies.

Zinc — 15 mg (150% NRV)

Provided as zinc citrate, a chelated form selected for bioavailability. Zinc is required as a cofactor for over 300 enzymatic processes, including those involved in keratin synthesis. Zinc is the subject of an authorised GB health claim for the maintenance of normal hair, skin, and nails.

The 15 mg daily dose is supplied at 150% of the Nutrient Reference Value, well within the UK Tolerable Upper Intake Level of 25 mg/day. This dose is appropriate for individuals not taking other zinc supplements; cumulative intake guidance applies.

Selenium — 55 µg (100% NRV)

Provided as selenomethionine, the form found in dietary protein sources. Selenium is required as a cofactor for selenoenzymes including glutathione peroxidase, which contributes to cellular antioxidant defences. Selenium is the subject of an authorised GB health claim for the maintenance of normal hair and nails.

The 55 µg daily dose is supplied at 100% of the Nutrient Reference Value, well within the UK Tolerable Upper Intake Level of 300 µg/day.


What we don't claim

The published research on the actives in HR01.1 has investigated many endpoints; hair count, hair density, shedding, tensile strength, scalp condition. Some of these studies have reported notable findings.

Under UK food law, only three claims about the actives in HR01.1 are formally authorised on the GB Nutrition and Health Claims Register: that Vitamin D3 contributes to the normal function of the immune system, that Zinc contributes to the maintenance of normal hair, skin and nails, and that Selenium contributes to the maintenance of normal hair and nails.

We make those three claims because they are authorised. We do not make claims about the other actives including Pumpkin Seed Oil, Saw Palmetto, Tocotrienol, and Ashwagandha, even though we have selected and dosed them based on the published research.

The formulation reflects the literature. The label reflects the regulatory framework. We are comfortable with the gap between the two, and we think you should understand it before you buy.


Reformulation philosophy

A formulation is a statement about what the published evidence currently supports. The evidence develops. So does the formulation.

When new published research changes our understanding of a dose, an active, or a contributor, HR01.1 is updated. Each revision is logged, dated, and explained on the Reformulation Log (coming soon). Subscription customers receive each new revision automatically when it is released.

This is the discipline that distinguishes a protocol from a product. A product is sold and forgotten. A protocol is maintained.


References

CITED IN THIS DOCUMENT

Cho YH, Lee SY, Jeong DW, et al. Effect of pumpkin seed oil on hair growth in men with androgenetic alopecia: a randomized, double-blind, placebo-controlled trial. Evidence-Based Complementary and Alternative Medicine. 2014;2014:549721. View paper →

Evron E, Juhasz M, Babadjouni A, Mesinkovska NA. Natural hair supplement: friend or foe? Saw palmetto, a systematic review in alopecia. Skin Appendage Disorders. 2020;6(6):329-337. View paper →

Beoy LA, Woei WJ, Hay YK. Effects of tocotrienol supplementation on hair growth in human volunteers. Tropical Life Sciences Research. 2010;21(2):91-99. View paper →

Lengg N, Heidecker B, Seifert B, Trüeb RM. Dietary supplement increases anagen hair rate in women with telogen effluvium: results of a double-blind, placebo-controlled trial. Therapy. 2007;4(1):59-65. View related review →

Almohanna HM, Ahmed AA, Tsatalis JP, Tosti A. The role of vitamins and minerals in hair loss: a review. Dermatology and Therapy. 2019;9(1):51-70. View paper →

Guo EL, Katta R. Diet and hair loss: effects of nutrient deficiency and supplement use. Dermatology Practical & Conceptual. 2017;7(1):1-10. View paper →

Chandrasekhar K, Kapoor J, Anishetty S. A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults. Indian Journal of Psychological Medicine. 2012;34(3):255-262. View paper →

Norwegian Scientific Committee for Food Safety (VKM). Risk assessment of "other substances" — L-cysteine and L-cystine. Opinion of the Panel on Nutrition, Dietetic Products, Novel Food and Allergy. 2016. View VKM publications →

RELATED REGULATORY DOCUMENTS

GB Nutrition and Health Claims Register, Department of Health and Social Care.
UK Tolerable Upper Intake Levels, Scientific Advisory Committee on Nutrition.
Food Standards Agency Committee on Toxicity, Ashwagandha Review (ongoing).